google-site-verification: google7d6f7bb0313f3584.html
Sampling of recent publications co-authored by Dr. Reeves
2022 Study on treatment of  carpal tunnel syndrome that comes back or persists after surgery. 
My colleague Dr. Chao from the  School of Medicine of the National Defense Medical Center in Taipai, Taiwan  retrospectively reviewed outcomes from consecutive patients he treated by  freeing up the median nerve under ultrasound guidance (hydrodissection) who had all failed  a first surgery for carpal tunnel syndrome (CTS), meaning symptoms were not relieved or came back. This is important  information because  the effect of current conservative management or revision surgery is unsatisfactory.  He reviewed records on 40 consecutive patients, and was able to capture data on 36 of 40.  Symptom relief ≥ 50% represented an effective outcome, while symptom relief < 50% was rated as a poor outcome. No patients reporrted worsening due to treatment. Nearly 2/3 (61.1%) of patients reported an effective outcome after a mean of 3.1 injections, with a post-injection follow-up mean of 33 (6–67) months.  
2022 study on how dextrose works: Potentially by protecting nerves against inflammation 
Dr. Wu from Taiwan studied human nerve cells, and stressed by exposure to a protein that kills nerve cells or makes them stop functioning.  The nerve were then surround by dextrose in various  concentrations to observe if dextrose blocked the stress effects  of the protein, called TNFα.  It did.  Take  a  look at this graph. On the left, 100% of the cells are functioning normally. On the right, the five bars are various concentrations of dextorse.  All it took to restore the metabolism of the nerve cells to normal was exposure to less than 1/2 percent of glucose.  The conclusion was glucose (dextrose in humans)  was protective. 
A significantly higher percentage of those with recurrent symptoms reported an excellent outcome, defined as a greater than 70% improvement (8/13 [61.6%] vs. 3/23 [13%], p = 0.006). Conclusion:  Hydrodissection with 5% dextrose may result in a clinically important and durable benefit in those experiencing persistent or recurrent CTS after surgery.
​2020  randomized controlled trial (RCT) on knee OA treatment published in Annals of Family Medicine
Dr. Regina Sit of the Chinese University of Hong Kong directed this study to show that small needle injection with dextrose improves knee pain and function in a level I (highest level of quality) randomized controlled trial.  There are many other pain sources around the knee that, when included in treatment, will result in more pain relief and functional improvement, but simple knee injection with dextrose is beneficial for pain and function, without requiring steroid injection.    Here is the conclusion, and for professionals a link to the PDF
CONCLUSION: Intra-articular dextrose prolotherapy injections reduced pain, improved function and quality of life in patients with KOA compared with blinded saline injections. The proc​edure is straightforward and safe; the adherence and satisfaction were high.
2021 article  on  what happens to white blood cells types when platelet rich plasma is made
This study, led by Dr. Ted Harrison from Victoria, British Columbia, Canada evaluated what happens to the proportion of various white blood cells during centrifugation in the process of making platelet rich plamsa. found a singificant increase in the proportion of lymphocytes and decrease in granulocytes.  Although this is preliminary work, it may be clinically relevant, because the distribution of white blood cells may affect clinical outcomes. 
2019  RCT on jaw (TMJ) pain and dysfunction published in Mayo Clinic Proceedings
Dr. Francois Louw of Vancouver, British Columbia, directed this level I randomized controlled trial demonstrating the benefit of a simple, reproducible, and effective tiny needle injection of the temporomandibular joint in participants suffering from substantial pain and dysfunction.  Here is a brief outcome statement, and for professionals a link to the PDF. 
Summary statement/conclusion: Pain and dysfunction improved by at least 50% in 38 of 54 (70%) and 39 of 54 (72%) jaws, respectively.   Intra-articular dextrose injection (prolotherapy) resulted in substantial improvement in jaw pain, function, and mouth opening ability compared with masked control injection at 3 months; clinical improvements endured to 12 months. Satisfaction was high.
Dr. Reeves received 2020 Lifetime Achievement Award
for research advances in the field of regenerative medicine and pain
​Recent International Lectures
October, 2020 Argentina (Virtual) for Latin American Association of Orthopedic medicine. 
October, 2019   Lima, Peru: Peruvian Association of Regenerative Medicine and Musculoskeletal pain
September, 2018, Seoul, South Korea: Severance Hospital, Yonsei Univesity
 Dr Reeves Kansas City, prolotherapy kcc,
​
Video: American Association of Orthopedic Medicine

Dr. Reeves Explains Why He Began Using Prolotherapy
Dr Reeves Most Recent Talk - December 2020